Futurefuel Corp (FF) 11.50 $FF Kinder Morgan-Southern

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Futurefuel Corp (FF) 11.50 $FF

Kinder Morgan-Southern Company Natural Gas Pipeline Deal
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:01AM CDT
Kinder Morgan, Inc. (KMI) and Southern Company (SO) have entered into a natural gas pipeline venture intended to enhance both companies' leadership in energy infrastructure development.
SOL: 1.20 (-0.03), KMI: 19.73 (-0.06), FF: 11.50 (unch), SO: 53.15 (-0.21)

BP's Strategic Initiatives to Counter Macro Risks Impress
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:59AM CDT
On Jul 8, 2016, we issued an updated research report on energy giant, BP plc (BP).
SOL: 1.20 (-0.03), BAK: 11.15 (-0.16), BP: 32.68 (-0.77), FF: 11.50 (unch)

Statoil Sells Edvard Greig Stake to Increase Share in Lundin
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:45AM CDT
Statoil ASA (STO) and Lundin Petroleum have concluded their earlier announced transaction, whereby the former has farmed out its entire stake of 15% in the Edvard Greig field in exchange of an increased shareholding in Lundin Petroleum.
SOL: 1.20 (-0.03), BAK: 11.15 (-0.16), FF: 11.50 (unch), STO: 15.48 (+0.08)

Kinder Morgan, Nucor Sign 10-Year Agreement Worth $900M
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:39AM CDT
Kinder Morgan Inc. (KMI) has inked a new 10-year agreement with Nucor Corporation (NUE) to supply in-plant services for five of the latter???s facilities.
SOL: 1.20 (-0.03), KMI: 19.73 (-0.06), BAK: 11.15 (-0.16), FF: 11.50 (unch)

BP's Tangguh Expansion Project Receives Approval for FID
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 3:00AM CDT
BP plc (BP), on behalf of Tangguh Production Sharing Contract Partners, declared that its Tangguh Expansion Project in the Papua Barat Province of Indonesia has received approval for the Final Investment Decision (FID).
SOL: 1.20 (-0.03), BAK: 11.15 (-0.16), BP: 32.68 (-0.77), FF: 11.50 (unch)

Continental Resources Hits 52-Week High on Oil Recovery
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:42AM CDT
Shares of leading oil producer Continental Resources, Inc. (CLR) hit a 52-week high of $45.92 during Thursday's trading session.
SOL: 1.20 (-0.03), CLR: 43.13 (+0.29), FF: 11.50 (unch), CVRR: 5.86 (+0.24)

Newfield Provides Interim Operational Update, Ups Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 8:48AM CDT
Newfield Exploration Company (NFX) provided a provisional operations update and increased production expectations for the second-quarter and full-year 2016.
SOL: 1.20 (-0.03), NFX: 42.32 (+0.77), BWP: 16.12 (-0.14), FF: 11.50 (unch)

Range Resources (RRC) Gets Approval to Spud Trinidad Well
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:32AM CDT
Range Resources Corp. (RRC) announced that it has received approval from the regulatory bodies in Trinidad to spud the MD 51-2 development well.
SOL: 1.20 (-0.03), FF: 11.50 (unch), RRC: 40.04 (+1.11), CVRR: 5.86 (+0.24)

Energen in Non-Core Assets' Purchase and Sale Agreements
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 8:28AM CDT
Energen Corp. (EGN) announced that it has signed purchase and sale agreements for its non-core Delaware Basin and San Juan Basin assets.
SOL: 1.20 (-0.03), EGN: 47.28 (+0.67), FF: 11.50 (unch), CVRR: 5.86 (+0.24)

Enterprise (EPD) to Build Third Cryogenic Plant in Delaware
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:39AM CDT
Enterprise Products Partners L.P. (EPD) intends to build a new cryogenic natural gas processing facility and related natural gas and natural gas liquids (NGL) pipeline infrastructure.
SOL: 1.20 (-0.03), FF: 11.50 (unch), CVRR: 5.86 (+0.24), EPD: 26.93 (+0.04)

BP on Track with the Atoll Phase One Project Development
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:35AM CDT
BP plc (BP), in association with the Egyptian Natural Gas Holding Company ("EGAS", has given consent for the development of the Atoll Phase One project.
SOL: 1.20 (-0.03), BP: 32.68 (-0.77), FF: 11.50 (unch), CVRR: 5.86 (+0.24)

ExxonMobil's Russian Project May Get Nod to Export to China
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:31AM CDT
ExxonMobil Corp.???s (XOM) oil and gas project on the Russian Pacific island of Sakhalin is likely to get rights to export natural gas to China.
SOL: 1.20 (-0.03), XOM: 86.93 (-0.11), FF: 11.50 (unch), CVRR: 5.86 (+0.24)

BP and Rosneft to Form Yermak Neftegaz LLC Joint Venture
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:28AM CDT
BP plc (BP) and Russian oil major Rosneft have inked a final binding agreement at the St Petersburg International Economic Forum ("SPIEF" to form a new joint venture (JV) - Yermak Neftegaz LLC.
SOL: 1.20 (-0.03), BP: 32.68 (-0.77), FF: 11.50 (unch), CVRR: 5.86 (+0.24)

FutureFuel Releases First Quarter 2016 Results
GlobeNewswire - Tue May 10, 4:07PM CDT
FutureFuel First Quarter Net Income Increases $2.5 Million
FF: 11.50 (unch)

FutureFuel to Release First Quarter Financial Results on May 10, 2016
GlobeNewswire - Wed May 04, 3:19PM CDT
FutureFuel Corp. (NYSE:FF) ("FutureFuel", a manufacturer of custom and performance chemicals and biofuels, announced today that it will release first quarter 2016 financial results after market close on Tuesday, May 10, 2016.
FF: 11.50 (unch)

Valero (VLO) Q1 Earnings Miss Estimates, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:28AM CDT
Valero Energy Corporation (VLO) posted adjusted first-quarter 2016 earnings of 60 cents per share that lagged the Zacks Consensus Estimate of 73 cents by 17.8%.
SOL: 1.20 (-0.03), VLO: 53.35 (+1.00), BAK: 11.15 (-0.16), FF: 11.50 (unch)

CNOOC (CEO) Q1 Revenues Decrease, Production Increases
Zacks Equity Research - Zacks Investment Research - Tue May 03, 7:57AM CDT
CNOOC Ltd. (CEO) reported first-quarter 2016 total revenue of 24.64 billion yuan (US$3.8 billion), down 30.7% year over year.
SOL: 1.20 (-0.03), BAK: 11.15 (-0.16), CEO: 114.15 (-1.08), FF: 11.50 (unch)

Eni (E) Q1 Loss Wider than Expected on Weak Gas Sales
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:01AM CDT
EniSpA's (E) first-quarter 2016 adjusted loss from continuing operations of 48 cents per American Depository Receipt/ADR (loss of ???0.22 per share) was substantially wider than the Zacks Consensus Estimate of loss of 8 cents.
SOL: 1.20 (-0.03), E: 29.51 (-0.06), BAK: 11.15 (-0.16), FF: 11.50 (unch)

FutureFuel Corp. Named by Forbes Magazine as One of Top 100 Most Trustworthy Companies in America
GlobeNewswire - Fri Apr 29, 3:03PM CDT
FutureFuel Corp. (NYSE:FF) has been named by Forbes Magazine as one of the Top 100 Most Trustworthy Companies in America. FutureFuel Corp. was named in the Small Caps ($250M - $1B) category. The selection is based on MSCI ESG Research's evaluation of the accounting and governance practices of publicly traded non-financial American companies. "It is an honor to be recognized as a Top 100 Most Trustworthy Company," stated CFO Rose Sparks, "in acknowledgement of our efforts on financial reporting and corporate governance. We pledge to continue our commitment to these best practices."
FF: 11.50 (unch)

Phillips 66 (PSX) Q1 Earnings Miss, Revenues Beat Estimates
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:35AM CDT
Phillips 66 (PSX) posted adjusted first-quarter 2016 earnings of $0.67 per share missing the Zacks Consensus Estimate of $0.86.
SOL: 1.20 (-0.03), PSX: 77.19 (+1.04), BAK: 11.15 (-0.16), FF: 11.50 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading